IMR Press / FBL / Volume 17 / Issue 1 / DOI: 10.2741/3912

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Purinergic signalling in osteoblasts
Show Less
1 The Mellanby Centre for Bone Research, Dept. Human Metabolism, The University of Sheffield, S10 2RX, UK
2 Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK
3 Musculoskeletal Biology Institute of Ageing and Chronic Disease, The University of Liverpool, Liverpool, L69 3GE, UK
Academic Editor:Elena Adinolfi
Front. Biosci. (Landmark Ed) 2012, 17(1), 16–29;
Published: 1 January 2012
(This article belongs to the Special Issue Purinergic signalling in bone and inflammation)

The skeleton is maintained throughout life via the finely tuned actions of osteoblasts and osteoclasts, with disruption in this balance eventually leading to bone disease. The exact mechanisms balancing these actions are not fully known, although several regulatory systems are known to be involved. The involvement of purinergic signalling in bone has come to light over the past 20 years or so. This review will highlight the current knowledge of purinergic signalling in osteoblasts - covering expression of P2 receptors, mechanisms of ATP release and degradation, P2 receptor mediated signalling and finally the functional consequences of P2 receptor signalling in bone.

extracellular ATP
P2 receptors
purinergic signalling
Back to top